NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors Journal Articles Refereed uri icon

Overview

Published in

  • Clinical Cancer Research

Time

Date/time value

  • 2004

Identity

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.ccr-03-0245

Additional Document Info

Parent Title

  • Clinical Cancer Research

Volume

  • 10

Issue

  • 8

Publisher

  • American Association for Cancer Research